- Stem cells isolated from a patient's own heart during surgery and later infused back in higher numbers may someday treat heart failure in patients with previous heart attacks.
- Patients treated with their heart stem cells had greater pumping power, and reported a better quality of life.
- Benefits continued to increase as long as two years after receiving the stem cells.
LOS ANGELES, Nov. 6, 2012 (GLOBE NEWSWIRE) -- Cardiac stem cells may one day be an effective treatment for heart failure caused by muscle scarring after a heart attack, according to late-breaking clinical trial results presented at the American Heart Association's Scientific Sessions 2012.
In the Effect of Cardiac Stem Cells In Patients with Ischemic CardiOmyopathy (SCIPIO) trial, heart function and quality of life improved in 20 people treated with their own cardiac stem cells (CSCs).
"This is exciting," said Roberto Bolli, M.D., lead author of the trial, chief of Cardiovascular Medicine and director of the Institute of Molecular Cardiology at the University of Louisville in Kentucky. "The effect of these cells has continued for up to two years, and has gotten stronger. There was also a major reduction in heart scarring."
In 33 patients with heart failure who had undergone coronary artery bypass surgery, researchers removed a tiny piece of heart tissue and isolated heart stem cells called c-kit CSCs. Researchers then grew additional cells to infuse into 20 volunteers assigned to treatment.
Among outcomes found two years after treatment:
- The 13 untreated control patients had no meaningful improvement in their hearts' pumping ability, contraction of the damaged wall of the heart or quality of life at 1 year. There was still no change in three patients followed for two years.
- The 20 treated patients had a significant increase in pumping ability — rising 7.0 percent at 4 months, 8.1 percent at one year and, for the eight patients who were followed longer, 12.9 percent at two years.
- Contracting ability of the scarred part of the heart in treated patients improved 7.6 percent at four months, 7 percent at one year and 18.4 percent at two years.
- Heart muscle scarring in nine treated patients who underwent cardiac magnetic resonance reduced significantly, from 34.9 grams before CSCs to 21.6 grams at four months and 18.7 grams at one year. Viable heart muscle increased by 11.6 grams at four months and 31.5 grams at one year.
- Quality of life, measured using an inverse scoring system, improved in the treatment group from 44.1 before CSCs to 25.1 at four months, 19.9 at one year and 22.8 at two years.
"We have not seen any deaths among the patients, or any adverse effects that can be ascribed to the stem cells," Bolli said.
About 6.6 million Americans suffer from heart failure, according to the American Heart Association. Life expectancy is about five years after diagnosis. Ischemic heart attacks cause most of the 57,000 U.S. deaths a year due to heart failure.
Larger, multi-center studies are needed to confirm the findings, Bolli said.
The Jewish Hospital, University of Louisville, and the National Institutes of Health funded the study. Co-authors' names are on the abstract.
Disclosures are here http://newsroom.heart.org/pr/aha/document/DISCLOSURES.pdf
For more information about heart failure, visit www.heart.org/heartfailure.
Follow news from the American Heart Association's Scientific Sessions 2012 via Twitter: @HeartNews.
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.
Note: The SCIPIO trial presentation is 11:30 a.m. PT, Tuesday, Nov. 6, 2012 in Hall G.
Any downloadable multimedia related to this news release is on the right column of the release link at
The American Heart Association logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=9940
For Media Inquiries:
AHA News Media in Dallas: (214) 706-1173
AHA News Media Office, Nov. 3-7,
at the Los Angeles Convention Center: (213) 743-6205
For Public Inquiries: (800)-AHA-USA1 (242-8721)
Source:American Heart Association